Results 11 to 20 of about 7,679 (193)

Elevated mepolizumab levels in patients with severe asthma responsive to 1 year’s mepolizumab treatment [PDF]

Journal of Allergy and Clinical Immunology: Global
Background: Asthma involves variable airflow limitation and persistent airway inflammation. Eosinophilic asthma, characterized by cytokine-mediated type 2 inflammation, is generally treated with inhaled corticosteroids.
Takayasu Nishimaki, MD, Hitoshi Sasano, MD, PhD, Sonoko Harada, PhD, Tomohito Takeshige, MD, PhD, Yuuki Sandhu, MD, PhD, Yuki Tanabe, MD, Kei Matsuno, MD, PhD, Tetsutaro Nagaoka, MD, PhD, Jun Ito, MD, PhD, Ryo Atsuta, MD, PhD, Mayu Ohuchi, PhD, Shigehiro Yagishita, MD, PhD, Akinobu Hamada, PhD, Kazuhisa Takahashi, MD, PhD, Norihiro Harada, MD, PhD   +14 more
doaj   +2 more sources

The clinical question of mepolizumab in the long-term treatment of idiopathic chronic eosinophilic pneumonia; how long should we use mepolizumab? [PDF]

Respiratory Medicine Case Reports
The efficacy of mepolizumab as an alternative to glucocorticoids for treating idiopathic chronic eosinophilic pneumonia (ICEP) has been reported. However, various questions remain unanswered, such as the most appropriate dose and dosage interval of ...
Masamitsu Hamakawa, Machiko Arita, Hiroshi Takahashi, Akihiko Amano, Nobuyoshi Hamao, Ayaka Tanaka, Akihiro Ito, Tadashi Ishida   +7 more
doaj   +2 more sources

Real-World Experience on the Use of Mepolizumab from the Severe Asthma Registry of the German Asthma Net (MepoGAN-Study) [PDF]

Journal of Asthma and Allergy, 2023
Stephanie Korn,1 Katrin Milger,2 Dirk Skowasch,3 Christian Schulz,4 Cordula Mohrlang,5 Martin Wernitz,5 Thomas Paulsson,6 Michael Hennig,5 Roland Buhl7 1IKF Pneumologie Mainz, Mainz and Thoraxklinik Heidelberg, Heidelberg, Germany; 2Department of ...
Korn S, Milger K, Skowasch D, Schulz C, Mohrlang C, Wernitz M, Paulsson T, Hennig M, Buhl R   +8 more
doaj   +1 more source

Mepolizumab for hypereosinophilic syndrome: effectiveness and safety from real-world evidence [PDF]

Frontiers in Immunology
Hypereosinophilic syndrome (HES) is a rare condition characterized by elevated eosinophil levels and related symptoms of eosinophil-mediated organ damage. We reviewed the effectiveness and safety of mepolizumab for the treatment of HES.
Elvira Mora, María Laura Fox, María Laura Fox, Angelina Lemes, Beatriz Velasco, Jesús María Hernández-Rivas, Jesús María Hernández-Rivas   +6 more
doaj   +3 more sources

Mepolizumab and oral corticosteroid stewardship - data from Australian Mepolizumab Registry [PDF]

, 2021
BACKGROUND: Oral corticosteroids (OCS) carry serious health risks. Innovative treatment options are required to reduce excessive exposure and promote OCS stewardship.
Thomas, Dennis, Hew, Mark, Harvey, Erin S, Upham, John W, Kritikos, Vicky, Peters, Matthew, Harrington, John, McDonald, Vanessa M, Stevens, Sean, Gillman, Andrew, Katelaris, Constance H, Bardin, Philip, Reynolds, Paul N, Sivakumaran, Pathmanathan, et al.   +14 more
core   +3 more sources

Real-world outcomes of mepolizumab treatment in severe eosinophilic asthma patients - retrospective cohort study in Slovakia [PDF]

, 2023
Aims. Mepolizumab, a fully-humanized recombinant IgG1 kappa monoclonal antibody directed against IL-5, has shown improved asthma control and lung function in randomised controlled trials.
Martina Ondrusova, Vaclav Vanecek, Milos Jesenak, Veronika Urdova, Ludek Hochmuth, Katarina Dostalova   +5 more
core   +1 more source

Safety and Efficacy of Mepolizumab in Hypereosinophilic Syndrome: An Open-Label Extension Study. [PDF]

, 2021
Background: A double-blind, placebo-controlled, phase III study (200622) showed that mepolizumab reduces disease flares for patients with uncontrolled FIP1-like-1-platelet-derived growth factor receptor α-negative hypereosinophilic syndrome (HES) and two
Reiter, Andreas, HES Mepolizumab Study Group, Faguer, Stanislas, Chupp, Geoffrey, Gleich, Gerald J, Bentley, Jane J.H., Steinfeld, Jonathan, Roufosse, Florence, Walz, Bastian, Yancey, Steven W   +9 more
core   +1 more source

Mepolizumab database [PDF]

, 2022
Mepolizumab ...
Jefferson Antonio Buendia Rodriguez
core   +1 more source

Safety and efficacy of monoclonal antibodies targeting IL-5 in severe eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials

Health Sciences Review, 2023
Background: Recently, mepolizumab and benralizumab have been approved for the treatment of severe eosinophilic asthma. Objective: Thus, the main objective of the current study was to find out the exact efficacy and safety profile of mepolizumab and ...
Noor Alam, S. Latha, Anoop Kumar
doaj   +1 more source

Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5. [PDF]

, 2022
Mepolizumab, an anti-interleukin-5 (IL-5) antibody, reduces disease flares in patients with hypereosinophilic syndrome (HES).
Rothenberg, Marc E, HES Mepolizumab Study Group, Faguer, Stanislas, Kwon, Namhee, Gleich, Gerald J, Steinfeld, Jonathan, Roufosse, Florence, Mavropoulou, Eleni, Yancey, Steven W   +8 more
core   +1 more source